CDTI
VC Fund
Ventura, United States
CDTi (NASDAQ: CDTI) is a cleantech emissions control company that designs, develops and manufactures sustainable solutions to reduce emissions of on- and off-road engine applications.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries CDTI invests in
SoftwareInformation TechnologyHealth CareBiotechnologyInternet
Stages CDTI invests in
Venture - Series UnknownSeedFunding RoundDebt FinancingGrant
Countries CDTI invests in
SpainUnited StatesMexico
Round sizes
Seed $314k–$2.8MVenture - Series Unknown $765k–$5.4M
Round size
- Seed
- $314k–$2.8M
- Venture - Series Unknown
- $765k–$5.4M
Investment Focus
Industry
- Software 9 (24%)
- Information Technology 7 (19%)
- Health Care 6 (16%)
- Biotechnology 6 (16%)
- Internet 4 (11%)
Stage
- Venture - Series Unknown 14 (38%)
- Seed 8 (22%)
- Funding Round 6 (16%)
- Debt Financing 3 (8%)
- Grant 2 (5%)
Country
- Spain 26 (70%)
- United States 4 (11%)
- Mexico 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PLD Space is a spanish innovative start-up company is to provide low cost and high reliability access to space. PLD Space offers suborbital and orbital launch services to its clients. | $40.1M / Series C / Oct 01, 2023 | ||
| Atlas Molecular Pharma is focused on the discovery of first-in-class, innovative therapeutics for the treatment of patients suffering from Rare and Ultra-Rare Diseases. Its line of work focuses on the development of a proprietary technology that enables the identification of molecules / drugs that provide stability to certain proteins whosedysfunction is responsible for the development of a large part of these rare diseases. | $3.4M / Venture - Series Unknown / Feb 01, 2022 | ||
| Oncovision (GEM Imaging S.A.) is a Spanish technologic start-up company created in 2003 with the initiative of the Corpuscular Physics Institute (CSIC) and the University of Valencia.They work in Molecular Vision applied to Health Sciences focusing in: cancer diagnosis and treatment, and advanced research in neurology, oncology, and cardiology.They are a company focused on Molecular Vision, which creates, develops and markets new medical technologies, global innovations with relevant clinical and economic advantages, often representing a breakthrough in current standards of diagnosis and treatment.ONCOVISION´s original, fresh technology, strong intellectual property, top-level clinical evidence, leading global reference centers, and pioneering protocols, is supported by its dynamic cross-functional team. ONCOVISION is opening unprecedented options in the treatment of cancer and serious cardiac and neurological diseases.Their team and the company’s technologies have been recognized by Spanish and European prestigious institutions. In 2007, the company was selected as one of the “20 Best Technologic Companies in Spain” and won the “National Medical Physics 2007 Congress Award” In 2008, it was one of the “20 Best Health Technology Companies in Europe” by the prestigious European Technology Tour, as well as finalist in the “National 25th Aniversary Enisa Award” Prof. Jose María Benlloch, active member of the company, won in 2008, the well-known “Jaime I” award. Scientists, technicians, and technologists of ONCOVISION have dozens of publications and presentations at scientific and medical conferences worldwide.Their shareholding, based in Valencia, was strengthened in August 2006 by the Spanish venture capital firm Bullnet, unifying its proven track in technological and management capabilities with companies in Spain and Portugal. The company is managed by a multi-task professional team with international experience.With proven clinical and scientific results, differentiated technology with enormous potential for future technological and financial capacity, intellectual property and developing lines, ONCOVISION is today ahead in the Spanish and European Health Industry. | $509.8K / Venture - Series Unknown / Jan 18, 2022 | ||
| Cella Medical Solutions allows surgeons to analyze and simulate complex surgery using the latest technologies, dramatically improving results. | $5.4M / Venture - Series Unknown / Jan 18, 2022 | ||
| Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology. | $1.4M / Venture - Series Unknown / Jan 18, 2022 | ||
| SummuS is a render farm, who offers 3D rendering and massive computing capabilites as a service. Companies demanding massive calculations for short periods of time can hire either the infraestructure or they can pay a price per Ghz per hour. This service allows them to avoid huge costs in hardware, personnel and system maintenance. | $764.7K / Venture - Series Unknown / Jan 18, 2022 | ||
| Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.Currently,cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance.Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market. | $3.3M / Venture - Series Unknown / Jan 18, 2022 | ||
| Elma is a health technology company on a mission to deliver better quality, more affordable and faster care by running an insurance business. The company was founded in 2017 and is based in Barcelona, Catalonia. | $494K / Jan 11, 2022 | ||
| Elma is a health technology company on a mission to deliver better quality, more affordable and faster care by running an insurance business. The company was founded in 2017 and is based in Barcelona, Catalonia. | $3.4M / Venture - Series Unknown / Jan 11, 2022 | ||
| A4CELL is a company that develops SPAchip (suspended planar-array chips) that help monitor living single cells. They offer SPAchips, as well as the CytoCHECK SPAchip and the CytoCHECK SPAchip. The company's goal is to increase the accuracy and quality of cell study data in order to better understand disease behavior. | $1.4M / Venture - Series Unknown / Dec 21, 2021 | ||
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
118,083 investors
Enterprise Investors
92,748 investors
Software Investors
57,577 investors
Health Care Investors
48,825 investors
Internet Investors
27,845 investors
Biotech Investors
24,243 investors
Biotechnology Investors
21,493 investors
SaaS VC Funds
72,248 investors
Enterprise VC Funds
59,211 investors
FAQ
What does CDTI invest in?
CDTI invests primarily in Software, Information Technology and Health Care startups, most often at Venture - Series Unknown and Seed stage. Most of the 37 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does CDTI invest in?
CDTI typically joins rounds of $314k–$2.8M at Seed and $765k–$5.4M at Venture - Series Unknown. These are whole funding-round sizes, not CDTI's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds CDTI took part in.
When did CDTI last invest?
The most recent investment recorded for CDTI closed in Oct 2023. Shizune tracks 37 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
